ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain in the United States

Read also

Gossamer Bio

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Amgen opens new drug substance

Amgen opens new drug substance facility in North Carolina, US

BIA report

BIA report: UK biotech investment surged to £3.5bn in 2024

MSD wins FDA

MSD wins FDA priority review for Welireg in rare endocrine cancer